Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23750/abm.v88i4-S.6792 http://scihub22266oqcxt.onion/10.23750/abm.v88i4-S.6792 29083351/?report=reader!6357653!29083351     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Biomed 2017 ; 88 (4S): 38-42 Nephropedia Template TP {{tp|p=29083351|t=2017. Rivaroxaban and early periprostethic joint infection: our experience |pdf=|usr=}}{{29083351}} gab.com Text Rivaroxaban and early periprostethic joint infection: our experience JO: Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=29083351 #FOAvip BACKGROUND AND AIM OF THE WORK: Periprostethic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. MATERIALS AND METHODS: We analyze our experience from 1st January 2015 to 31th December 2016. We consider all consecutive hip arthroplasty implants in this period. RESULTS: In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. CONCLUSIONS: In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. Twit Text FOAVip Rivaroxaban and early periprostethic joint infection: our experience ????Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=29083351 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29083351 #FOAvip English Wikipedia <ref>{{Cite pmid|29083351}}</ref> Rivaroxaban and early periprostethic joint infection: our experience #MMPMID29083351 Di Benedetto P; Zangari A; De Franceschi D; Di Benedetto ED; Cainero V; Beltrame A; Gisonni R; Causero A Acta Biomed 2017[Oct]; 88 (4S): 38-42 PMID29083351show ga BACKGROUND AND AIM OF THE WORK: Periprostethic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. MATERIALS AND METHODS: We analyze our experience from 1st January 2015 to 31th December 2016. We consider all consecutive hip arthroplasty implants in this period. RESULTS: In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. CONCLUSIONS: In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. |Aged[MESH] |Arthroplasty, Replacement, Hip/*adverse effects[MESH] |Arthroplasty, Replacement, Knee/adverse effects[MESH] |Factor Xa Inhibitors/*adverse effects[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Prosthesis-Related Infections/*etiology[MESH] |Retrospective Studies[MESH]Rivaroxaban and early periprostethic joint infection: our experience (epmc).pdf DeepDyve Pubget Overpricing